ClinicalTrials.gg
CompletedNCT05697666Updated Jan 26, 2023

Impact of the Depth of Neuromuscular Blockade on Respiratory Mechanics in Moderate to Severe ARDS Patients

An observational study in Acute Respiratory Distress Syndrome and Ventilator-Induced Lung Injury, sponsored by Centre Hospitalier de Saint-Brieuc. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Centre Hospitalier de Saint-Brieuc · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
33
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Respiratory Distress Syndrome with a site in France — 41 open to participants now, 43 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.

Enrollment
80th of 97
33 · median 80
Started
2020
with 60 others
Observational
98 of 217
19 open now
Registered
175th of 217
by date

Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 80th largest by enrollment of the 97 observational ones that give a count, is one of 61 that started in 2020, is one of 98 observational ones, and was the 175th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

41 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Respiratory Distress Syndrome with a site in France, or all of them as a file.
02

Study summary

Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory mechanics by reducing ventilator induced lung injuries (VILI), especially the so called atelectrauma. Although its monitoring is recommended in clinical practice, data about the depth of NMB necessary for an effective relaxation of the thoracic and diaphragmatic muscles and, therefore, the reduction of the chest wall elastance, are scarce. The investigators hypothesised that complete versus partial NMB can modify respiratory mechanics and its partitioning.

Read the detailed description

The investigators conducted a prospective study to compare the respiratory mechanics of patients with moderate to severe ARDS according to the NMB depth, using an oesophageal pressure catheter (NutriVent®, Sidam) for transpulmonary pressure (PL) assessment, and facial train of four (TOF) for neuromuscular blockade monitoring. The oesophageal balloon was calibrated according to the method recently described to estimate the individual target volume which is assumed to be more adequate. Each patient was analysed at two different times: deep NMB (TOF = 0) and intermediate to light NMB (TOF > 0). The mechanical ventilation parameters were identical for these two measurements. The primary endpoint was the proportion of patients with expiratory transpulmonary pressure (PLexp) greater than or equal to 0 according to the NMB level, in order to assess the risk of region-dependent atelectasis and alveolar opening/closing injury (atelectrauma). Secondary endpoints included: the impact of the depth of NMB on other partition parameters of respiratory mechanics, and the variability of results according to the type of oesophageal balloon calibration.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Ventilator-Induced Lung Injury

Keywords

  • Oesophageal pressure
  • Transpulmonary pressure
  • Train of four
  • Neuromuscular blockade
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population includes mainly pulmonary ARDS with a predominance of SARS-CoV2 pneumonia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe ARDS patients with PaO2/FiO2 ratio \< 150 mmHg
  • Mechanical ventilation, deep sedation and neuromuscular blockade with continuous infusion of cisatracurium for more than 24 hours
  • Presence of an oesophageal catheter
  • Written

Exclusion criteria

Exclusion Criteria:

  • of oesophageal catheter
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
33 participants (actual)
Patient registry
No

Groups and cohorts

  • Moderate to severe ARDS adult patients under mechanical ventilation and neuromuscular blockade

    no intervention

    Other: Modulation of the depth of the neuromuscular blockade

Interventions

  • OtherModulation of the depth of the neuromuscular blockade

    Analysis of the respiratory mechanics at two times: * Facial train of four = 0, indicating a deep neuromuscular blockade * Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade

06

What researchers measure

Primary outcomes

  1. Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0

    Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0 according to the level of neuromuscular blockade (%)

    Time frame: one day

Secondary outcomes

  1. Inspiratory transpulmonary pressure

    Inspiratory transpulmonary pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  2. Respiratory system compliance

    Respiratory system compliance according to the level of neuromuscular blockade (ml/cmH20)

    Time frame: one day

  3. Chest wall elastance

    Chest wall elastance according to the level of neuromuscular blockade (cmH2O/l)

    Time frame: one day

  4. Pulmonary elastance

    Pulmonary elastance according to the level of neuromuscular blockade (cmH2O/l)

    Time frame: one day

  5. Driving pressure

    Driving pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  6. Transpulmonary driving pressure

    Transpulmonary driving pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  7. Plateau pressure

    Plateau pressure according to the level of neuromuscular blockade (cmH20)

    Time frame: one day

  8. Oesophageal balloon calibration

    Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0 according to the oesophageal balloon calibration volume (%)

    Time frame: one day

07

Study locations

1 site
  • Centre Hospitalier de Saint Brieuc
    Saint-Brieuc, Brittany 22000, France
08

References and documents

Publications

  • Akoumianaki E, Maggiore SM, Valenza F, Bellani G, Jubran A, Loring SH, Pelosi P, Talmor D, Grasso S, Chiumello D, Guerin C, Patroniti N, Ranieri VM, Gattinoni L, Nava S, Terragni PP, Pesenti A, Tobin M, Mancebo J, Brochard L; PLUG Working Group (Acute Respiratory Failure Section of the European Society of Intensive Care Medicine). The application of esophageal pressure measurement in patients with respiratory failure. Am J Respir Crit Care Med. 2014 Mar 1;189(5):520-31. doi: 10.1164/rccm.201312-2193CI. PubMed 24467647 ↗
  • Alhazzani W, Belley-Cote E, Moller MH, Angus DC, Papazian L, Arabi YM, Citerio G, Connolly B, Denehy L, Fox-Robichaud A, Hough CL, Laake JH, Machado FR, Ostermann M, Piraino T, Sharif S, Szczeklik W, Young PJ, Gouskos A, Kiedrowski K, Burns KEA. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. Intensive Care Med. 2020 Nov;46(11):1977-1986. doi: 10.1007/s00134-020-06227-8. Epub 2020 Oct 26. PubMed 33104824 ↗
  • Guervilly C, Bisbal M, Forel JM, Mechati M, Lehingue S, Bourenne J, Perrin G, Rambaud R, Adda M, Hraiech S, Marchi E, Roch A, Gainnier M, Papazian L. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017 Mar;43(3):408-418. doi: 10.1007/s00134-016-4653-4. Epub 2016 Dec 24. PubMed 28013329 ↗
  • Baedorf Kassis E, Train S, MacNeil B, Loring SH, Talmor D. Monitoring of neuromuscular blockade: a comparison of train-of-four and the Campbell diagram. Intensive Care Med. 2018 Dec;44(12):2305-2306. doi: 10.1007/s00134-018-5420-5. Epub 2018 Oct 22. No abstract available. PubMed 30350170 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Feb 2022, 24 months.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 24 months is close to that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Jan 26, 2023
StartActual
Feb 1, 2020
Primary completionActual
Feb 1, 2022
CompletionActual
Feb 28, 2022
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05697666
Lead sponsor
Centre Hospitalier de Saint-Brieuc
Responsible party
Nicolas Barbarot (Principal investigator. MD, Intensive Care Unit, Centre Hospitalier de Saint-Brieuc, Centre Hospitalier de Saint-Brieuc) — Principal investigator
First posted
Jan 26, 2023
Start date
Feb 1, 2020
Primary completion
Feb 1, 2022
Completion
Feb 28, 2022
Last update
Jan 26, 2023

Study contacts

Nicolas BARBAROT, MD
principal investigator · Centre Hospitalier Saint Brieuc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion